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Immune homeostasis is critically regulated by the balance between activating and inhibitory 
receptors expressed on various immune cells such as T and B lymphocytes, and myeloid cells. 
The inhibitory receptors play a fundamental role in the immune-checkpoint pathway, thus 
maintaining peripheral tolerance. We recently found that expression of leukocyte 
immunoglobulin-like receptor (LILR)B4, an inhibitory member of the human LILR family, is 
augmented in autoantibody-producing plasmablasts/plasma cells of systemic lupus 
erythematosus (SLE) patients. However, the mechanism behind the “paradoxical” 
upregulation of this inhibitory receptor upon pathogenic antibody-secreting cells is yet to be 
known. To this end, in this study we examined if glycoprotein 49B (gp49B), the murine 
counterpart of human LILRB4, is also elevated in autoantibody-producing cells in several 
SLE mouse models, and tried to clarify the underlying mechanism. We found that gp49B is 
expressed on plasma cells of lupus-prone models but not of healthy C57BL/6 mice, and the 
level was positively correlated to the anti-double-stranded DNA IgG titer in serum. Gp49B 
genetic deletion, however, did not abolish the serum autoantibodies or fully ameliorate the 
lethal glomerulonephritis, indicating that gp49B is not the sole regulator of lupus but a 
pathogenic element in the disease. We conclude that the elevated expression of this inhibitory 
receptor on pathogenic plasma cells was also relevant upon the murine SLE model. The 
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Inhibitory receptors play an important part in the immune checkpoint pathway, because 
achieving a balance between activation and inhibitory actions in the immune system is crucial 
for effective immune responses to pathogens, and simultaneous protection of self from 
autoimmune responses (1). Most inhibitory receptors exert inhibitory actions through 
immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in their cytoplasmic tails to recruit 
SH2-domain containing tyrosine phosphatases: SHP-1 and SHP-2 or lipid phosphatases: 
SHIP-1 and SHIP-2 (1, 2). In T lymphocytes, the co-inhibitory receptors CTLA-4 and PD-1 
are pivotal regulators for the initial and later stages of T cell activation, respectively (3, 4). 
Depletion of CTLA-4 and/or PD-1 perturbs the regulatory T cell function to suppress T cell 
priming and to maintain tolerance, resulting in murine experimental autoimmune thyroiditis 
or type I diabetes (5-7). In B lymphocytes, the loss of counterbalancing effects of inhibitory 
receptors such as FcγRIIb, CD22 and Siglec-G can lead to the development of autoimmune 
diseases like systemic lupus erythematosus (SLE) involving the production of a series of anti-
nuclear autoantibodies such as those against double-stranded DNA (dsDNA) (1, 8). Disease 
susceptibility in the majority of SLE mouse models (NZB, BXSB, SB/Le and MRL) (9), as 
well as SLE patients (10, 11), is associated with polymorphisms of FCGR2B, which encodes 
FcγRIIb. In support of this, we reported that the genetic combination of FCGR2B−⁄− and 
SLAM129 led C57BL/6 (B6) mice prone to glomerulonephritis with the elevation of the serum 
level of anti-nuclear autoantibodies (12).  
 
Murine glycoprotein 49B (gp49B), a 49-kDa membrane protein, is another inhibitory 
receptor with two ITIMs in its cytoplasmic tail. It belongs to the immunoglobulin (Ig) 
superfamily with another family member, gp49A, that harbors no specific signaling motifs 
(13-15). Gp49B was first reported regarding its expression and inhibitory action on bone 
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marrow-derived mast cells (BMMCs) (14, 16). When co-ligated with FceRI on BMMCs, 
gp49B inhibits mast cell exocytosis by recruiting SHP-1 (16, 17). The suppressive function of 
gp49B in innate and adaptive inflammation is executed by neutrophils (18) and mast cells 
(19), respectively. In our previous study, gp49B on dendritic cells was found to play a 
suppressive role in preventing excessive activation of T cells in vitro and in vivo (20). Among 
naïve cells in the hematopoietic system, gp49B is reported to be expressed only on Mac-1+ 
and Gr-1+ myeloid cells. However, expression of gp49B can be induced upon in vitro 
stimulation or in vivo infection. For instance, upon exposure to murine cytomegalovirus or 
Listeria monocytogenes, gp49B is expressed on natural killer cells, and then suppresses 
cytokine release (21). In the B cell lineage, gp49B was discovered on mature marginal zone 
B (MZB) cells and memory B cells, but not on naïve B cells. It exerts an inhibitory effect on 
the differentiation of MZB cells and memory B cells into plasmablasts or plasma cells, and 
subsequent antibody production (22).   
 
The human counterpart of gp49B is considered to be leukocyte Ig-like receptor (LILR)B4 
(B4, also known as ILT3 or CD85k) based on their syntenic chromosomal locations and 
structural similarities (23, 24). B4, together with other LILRB members, is an inhibitory 
isoform of the LILR family that negatively regulates immune responses via tolerized antigen-
presenting cells (25). Differing from mouse gp49B, B4 is not expressed on memory B cells, 
but on plasmablasts of healthy individuals (26). Interestingly, the expression of B4 was found 
to be increased on plasmablasts/plasma cells from SLE patients (27), and these B4high cells 
contained abundant anti-dsDNA Ig VH transcripts, suggesting a contradictory role of this 
inhibitory receptor as a pathogenic marker. However, the link between elevated B4 
expression and autoantibody production has yet to be elucidated.  
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In this study, we aimed at clarifying if murine gp49B expression is indeed upregulated on 
plasma cells of SLE model mice, as in human SLE patients, and if so, attempted to elucidate 
the pathogenic role of the augmented gp49B expression in autoimmunity such as in 
autoantibody production and glomerulonephritis. We found that lupus-prone mice, but not 
healthy strain C57BL/6 ones, exhibited gp49B expression on their plasma cells. The genetic 
deficiency of gp49B tended to slightly ameliorate SLE disease in BXSB/Y chromosome-
linked autoimmune accelerator (Yaa) mice, because the anti-dsDNA IgG level in serum was 
reduced, survival rate mildly improved, and PAS-positive deposition in the kidneys was 
reduced, although this genetic defect did not abolish autoantibodies in serum or eliminate the 
antibody-secreting cells in spleens from BXSB/Yaa mice. These results suggest that gp49B 
paradoxically plays a pathogenic role in autoantibody production and glomerulonephritis.  
 




C57BL/6 (B6) and non-obese diabetic NOD/ShiJcl (NOD) mice were purchased from CLEA 
Japan (Kawasaki, Japan). BXSB/MpJJmsSlc- Yaa (BXSB/Yaa), MRL/MpJJmsSlc-lpr/lpr 
(MRL/lpr) and Slc:NZBWF1((NZB × NZW) F1) mice were purchased from Japan SLC 
(Shizuoka, Japan). FcgRIIB (RIIB)-deficient mice with the B6 background excepting 129-
derived SLAM locus (RIIB−⁄−SLAM129) (28) and gp49B-deficient mice (gp49B−⁄−) with the B6 
background (20) were used. Gp49B-deficient RIIB−⁄−SLAM129 mice 
(gp49B−⁄−RIIB−⁄−SLAM129) were generated by crossing gp49B−⁄− mice with RIIB−⁄−SLAM129 
mice. Gp49B-deficient BXSB/Yaa mice (gp49B−⁄−BXSB/Yaa) were generated by crossing 
gp49B−⁄− mice with BXSB/Yaa mice for at least 7 generations. All mice were maintained and 
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bred in the animal facility of the Institute of Development, Aging and Cancer, Tohoku 
University, under specific pathogen-free conditions. All animal protocols were reviewed and 
approved by the Animal Studies Committee of Tohoku University. 
 
Flow cytometry analysis and cell sorting 
 
Single cell suspensions were prepared from spleens and bone marrow after red blood cell 
depletion by ammonium chloride lysis. Cells were stained for 30 min on ice in phosphate-
buffered saline (PBS) containing 2% fetal calf serum (FCS) with different combinations of 
the following antibodies conjugated with FITC or Alexa FluorÒ 488, PE, PerCP-Cy5.5, APC 
or Alexa FluorÒ 647, Pacific BlueTM, or biotin: anti-mouse CD21/CD35 (BD Biosciences, 
San Jose, CA, USA), anti-mouse CD11b, anti-mouse CD19, anti-mouse CD23, anti-
mouse/human CD45R/B220, anti-mouse CD85k (gp49 receptor) and anti-mouse CD138 
(Syndecan-1) (Biolegend, San Diego, CA, USA). Samples were analyzed and sorted using 
FACSAria III (BD Biosciences). Data were collected using FACS Diva software (BD 
Biosciences) and analyzed using FlowJo software (Tree Star, Inc., Ashland, OR, USA). Cells 
were analyzed or sorted based on the following gating: plasma cells (B220−CD138high), 
follicular B cells (CD19+CD21+CD23high), marginal zone B cells (CD19+CD21highCD23low), 
and monocytes (B220−CD11b+). Sorted cells were suspended in RPMI 1640 medium 
supplemented with 10% FCS, 1% penicillin/streptomycin and 50 µM 2-mercaptoethanol. 
 
Detection of antibodies by enzyme-linked immunosorbent assay (ELISA)  
 
(a) Anti-dsDNA antibody ELISA. Flat-bottom 96-well plates were coated with 0.001% 
protamine sulfate in distilled water for 60 min, followed by 5 μg/ml of double-stranded calf 
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thymus DNA (Sigma-Aldrich, St. Louis, MO, USA) diluted in 0.015 M sodium citrate with 
0.15 M NaCl (pH8.0) for 90 min. Plates were blocked with 1% bovine serum albumin (BSA) 
(Sigma-Aldrich) in PBS for 60 min. Serum samples were diluted to 1:100 with 1% BSA in 
PBS. Anti-dsDNA antibodies were detected with horseradish peroxidase (HRP)-conjugated 
goat anti-mouse IgG and IgM (Bethyl Laboratories, Inc., Montgomery, TX, USA) for 60 min, 
followed by 3,3’,5,5’-Tetramethylbenzidine (TMB) substrate (Invitrogen, Thermo Fisher 
Scientific, Waltham, MA, USA). Reactions were terminated with 1% hydrochloric acid and 
then the optical density was read at 450nm. 
(b) Total IgG and IgM ELISA. The levels of IgG and IgM were measured with the respective 
Mouse ELISA Quantitation Sets (Bethyl Laboratories), according to the manufacturer’s 
protocols with slight modifications. Optimization of serum dilution for each test is required.  
 
Detection of antibody-secreting cells (ASCs) by enzyme-linked immunospot (ELISpot) 
 
To detect anti-dsDNA IgG or IgM ASCs, 96-well filter plates with 0.45 μm pore size 
hydrophobic PVDF membrane (Merck Millipore, Burlington, MA, USA) were pre-coated 
with 0.1% methylated BSA (Sigma-Aldrich), followed by 10 μg/ml DNA coating and 1% 
BSA in PBS as a blocking reagent. Detection of total IgG or IgM was performed by coating a 
plate with 15 μg/ml goat anti-mouse IgG or IgM (Bethyl Laboratories). Spots were revealed 
with HRP-conjugated goat anti-mouse IgG or IgM (Bethyl Laboratories), following 3-amino-
9-ethylcarbazole (AEC) treatment.       
 
Detection of blood urea nitrogen 
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Blood urea nitrogen level was determined using a Urea N B kit from Wako Pure Chemical 
Industries (Osaka, Japan), according to the manufacturer’s protocol with slight modifications. 
The volumes of reagents used were downsized according to the maximum volume of serum 
sample available.               
 
Qualitative analysis of anti-nuclear antibodies (ANAs) 
 
Human epithelial type 2 (HEp-2) cell substrate slides from a Fluoro HEPANA test kit (MBL, 
Nagoya, Japan) were used, and the procedure was based on the manufacturer’s protocol with 
slight modifications. Serum samples were diluted to 1:40 with 1% BSA in PBS. Substrate 
slides were incubated with diluted serum samples for 45 min at room temperature, followed 
by washing three times with PBS (each time for 5 min). ANAs were detected with Alexa 
Fluor 488 goat anti-mouse IgG (Life Technologies, Carlsbad, CA, USA). Staining patterns 
were visualized and images were captured with a fluorescence microscope (BZ-9000 




Kidneys were fixed with 4% paraformaldehyde in phosphate buffer. Paraffin-embedded 
samples were sectioned at 2 µm, and then stained with hematoxylin and eosin (HE) or 
periodic acid-Schiff (PAS). By using ImageJ software (W. Rasband, National Institutes of 
Health, Bethesda, MD, USA), a grid was superimposed on a kidney section captured at 400 × 
magnification. The total area of the glomerulus was determined by counting intersecting 
points on the grid in the glomerular area within Bowman’s capsule. The percentage of PAS 
positive deposition was calculated with the formula below: 
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   no. of points falling on PAS-positive area 
% of PAS positive = _____________________________________ × 100% 
   total no. of points falling on glomerular area 





Statistical analyses were carried out using GraphPad Prism® 6 (Version 6.0; GraphPad 
Software, San Diego, CA, USA) based on results of at least three independent experiments. 
Data are represented when appropriate as means ± SEM. Data were compared for statistical 
differences by one-way ANOVA with Dunn’s multiple comparisons test, Pearson’s 
correlation coefficients with two-tailed test, two-way ANOVA with Sidak’s multiple 
comparisons test, two-tailed unpaired Student’s t-test with Welch’s correction or two-tailed 
paired or ratio paired Student’s t-test as stated in the figure legends. We considered p < 0.05 
as being statistically significant. 
 
Results and Discussion 
 
gp49B is expressed on plasma cells from autoimmune-prone mice 
 
The expression of gp49B on B-lineage cells has been reported on marginal zone B (MZB) 
cells and memory B cells from wild type B6 mice (22). To examine the expression of gp49B 
on B cell subsets, particularly on plasma cells from SLE model mice, flow cytometry analysis 
was performed on spleen and bone marrow cells from wild type B6 mice and SLE model 
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BXSB/Yaa mice. Gp49 was expressed on MZB cells of B6 mice as reported, and also on 
those of BXSB/Yaa mice (Fig. 1A). Interestingly, plasma cells from spleens and bone 
marrow of BXSB/Yaa mice were found to exhibit robust expression of gp49, compared to in 
control BXSB female mice and B6 mice (Fig. 1B). High surface expression of gp49 was also 
noted on splenic plasma cells from other SLE mouse strains such as FcgRIIB-deficient 
SLAM129, MRL/lpr and (NZB × NZW) F1 mice as well as type I diabetes model NOD mice 
(Fig. 1B). These results coincide with our previous finding for SLE patients, i.e., 
plasmablasts/plasma cells from peripheral blood of the patients exhibited high expression of 
LILRB4 (the human counterpart of gp49B) compared to healthy controls (27). We confirmed 
that gp49B, but not the ITIM-less isoform gp49A, is the major subtype expressed on plasma 
cells by flow cytometry analysis of gp49B-deficient BXSB/Yaa and FcgRIIB-deficient 
SLAM129 mice (Fig. 1C).  
 
Relation of gp49B expression to the anti-dsDNA IgG serum level in BXSB/Yaa and 
FcgRIIB−⁄−SLAM129 mice 
 
We have previously shown that the LILRB4 expression level on plasmablasts/plasma cells 
was reduced in SLE patients after medical treatment (27). Therefore, we then checked if 
murine gp49B is correlated to disease development in lupus-prone mice, by performing 
correlation studies. We noted a significant correlation between the expression level of gp49B 
on splenic plasma cells and the serum titer of anti-dsDNA antibodies in BXSB/Yaa mice, and 
this was more evident in the IgG class than the IgM class (Fig. 2A). It was also observed that 
the gp49B level gradually increased along with disease progression and reached its peak at 
around 15–20 weeks old of age in BXSB/Yaa mice and then decreased as the mice aged (Fig. 
2B).  
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To detect any influence of gp49B reduction on the serum autoantibody level, we then 
established a gp49B knockout model in the BXSB/Yaa and FcgRIIB−⁄−SLAM129 backgrounds. 
Unexpectedly, gp49B genetic deletion in these model mice did not abolish serum anti-
dsDNA autoantibodies. Gp49B−⁄−BXSB/Yaa mice, however, exhibited a significant decrease 
in serum anti-dsDNA IgG but not the IgM class autoantibody when compared to 
gp49B+/+BXSB/Yaa mice (Fig. 2C). On the other hand, FcgRIIB−⁄−SLAM129 female mice 
showed a later increase of the anti-dsDNA IgG/IgM autoantibody level in serum than 
BXSB/Yaa mice. Gp49B−⁄−FcgRIIB−⁄−SLAM129 female mice exhibited a significantly lower, 
but not diminished, level of anti-dsDNA IgG at around 36 weeks old and a comparable level 
of the IgM class autoantibody at all ages (Fig. 2D). To determine the knockout effect on 
antibody-secreting cells, anti-dsDNA antibody-secreting plasma cells from spleens were 
detected by ELISpot assay. While gp49B deletion in BXSB/Yaa mice significantly decreased 
the total number of anti-dsDNA IgG-secreting cells, the frequencies in spleens were grossly 
comparable to gp49B-sufficient BXSB/Yaa mice (Fig. 2E). Gp49B deficiency in 
FcgRIIB−⁄−SLAM129 mice did not cause a significant difference in the total number or 
frequency of pathogenic plasma cells (Fig. 2F). Examination of HEp-2-cell staining profiles 
of anti-nuclear autoantibodies (ANAs) for serum samples from gp49B−⁄−BXSB/Yaa mice 
revealed no significant alterations in them (Supplementary Fig. S1). These results indicate 
that the gp49B expression level is positively correlated to the serum anti-dsDNA IgG level in 
both the BXSB/Yaa and FcgRIIB−⁄−SLAM129 strains, while genetic deletion of gp49B did not 
abolish the autoantibody IgG, but reduced the anti-dsDNA IgG serum level due partly to the 
reduction in the number of the antibody-secreting cells in spleens. 
 
Partial amelioration of autoimmunity in gp49B−⁄−BXSB/Yaa mice 
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We then wanted to elucidate the pathology of gp49B-deleted BXSB/Yaa mice in order to 
determine how much influence on the autoimmune disease the gp49B genetic deletion had. 
The gp49B−⁄−BXSB/Yaa mice showed improved survival rate (Fig. 3A). To check the 
pathology of glomerulonephritis, we stained kidney sections with HE and PAS, and found 
that the gp49B-deficient BXSB/Yaa mice exhibited less severe glomerulonephritis, as 
indicated by tendency of the reduction of the glomerular PAS-positive deposits (Fig. 3B and 
3C). We also checked blood urea nitrogen (BUN) in serum in the gp49B-deficient BXSB/Yaa 
mice, but found no significant changes or correlations to the mildly ameliorated 
glomerulonephritis (Supplementary Fig. S1B).   
 
To detect any changes in cell populations other than that of plasma cells of gp49B-deficient 
BXSB/Yaa mice, we measured the splenic T and B cell as well as monocyte-macrophage 
populations (Fig. 4). We found a significant increase of the CD19+ B cells but not T cells (Fig. 
4A). BXSB/Yaa mice are known to have depleted marginal zone B (MZB) cells (29), and an 
increase in peripheral monocytes (30). Interestingly, we found that gp49B−⁄−BXSB/Yaa mice 
regained the MZB cell population in the spleen as well as splenic follicular B (FoB) cells (Fig. 
4B). The CD21 expression level on FoB cells was also increased in gp49B−⁄−BXSB/Yaa mice 
(Fig. 4C). This observation was similar to that for BXSB mice without the Yaa mutation, in 
which the intensity of CD21 on FoB cells was much lower in BXSB/Yaa mice (29). On the 
other hand, we observed a slight, but not significant, decrease in splenic monocytes from 
gp49B-deficient BXSB/Yaa mice (Fig. 4D), which might be related to the ameliorated kidney 
inflammation.  
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Collectively, we found that gp49B is expressed on plasma cells from lupus-prone, but not 
healthy mice. The expression level of gp49B was correlated with the serum titer of anti-
dsDNA autoantibodies. However, genetic deletion of gp49B did not result in abrogation of 
the autoantibodies, but a slight decrease in the serum autoantibody IgG level. We also noted a 
modest improvement in survival rate with mild amelioration of glomerulonephritis. These 
results indicate that gp49B is not the sole regulator of lupus but a pathogenic element in the 
disease. 
 
Defective in inhibitory receptors or a deficiency of them has been associated with the 
development of autoimmune disease in mice (1, 8). The presence of inhibitory receptors, for 
instance FcγRIIb, on plasma cells regulates their survivability and persistency in the bone 
marrow niche, thereby controlling antibody production (31). This could explain why 
plasmablasts or plasma cells from SLE-prone mice or patients exhibit reduced expression of 
FcγRIIb, to avoid apoptosis through FcγRIIb cross-linking (31). In contrast, we discovered 
up-regulation of gp49B on plasma cells from SLE-prone mice (BXSB/Yaa, MRL/lpr, NZBW 
F1, RIIB−⁄−SLAM129) in this study, which coincides with augmented expression of human 
LILRB4 on plasmablasts/plasma cells from acute-phase SLE patients (27). We hypothesized 
that gp49B plays the opposite role from FcγRIIb, where gp49B inhibits apoptosis of plasma 
cells, which should be examined in the next step by referring signaling events in B-lineage 
cells including plasma cells from SLE-prone mice upon stimulation.   
 
In BXSB/Yaa mice, we observed a relatively higher expression of gp49B on the plasma cells 
around 15–20 weeks old, and its expression reduced thereafter. This change of level is also 
reflected on the serum titer of IL-6 in BXSB/Yaa as reported (32), in which the level of IL-6 
is peaked around 3–4.5-month-old BXSB/Yaa mice. It is correlated with changes of disease 
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manifestations such as serum titer of ANA and anti-dsDNA antibodies (32). This implies that 
the surface expression of gp49B could indicate the severity of disease in BXSB/Yaa mice. 
Indeed, when we deleted gp49B gene in BXSB/Yaa, we observed a reduction of anti-dsDNA 
IgG serum titer and its antibody-producing cells in the spleen. BXSB/Yaa mice have a 50% 
of mortality rate at 6 months of age, and the major cause of death is the development of 
immune complex-mediate glomerulonephritis (33). A milder glomerulonephritis observed in 
the gp49B-deficient BXSB/Yaa mice could contribute to the improved survival in these mice.  
 
Although we did not demonstrate how gp49B has the direct effect on development of 
glomerulonephritis in BXSB/Yaa mice, based on our finding on the reduction of anti-dsDNA 
IgG titer, this might lead to slight amelioration of lupus nephritis. Presence of anti-dsDNA 
antibodies could contribute to the pathogenesis of glomerulonephritis as lupus nephritis can 
be induced in healthy mice by introducing pathogenic autoantibodies from lupus-prone mice 
(34), or incorporating transgene encoded anti-dsDNA IgG into normal mice (35).   
 
Differ from BXSB/Yaa mice, symptoms lead to fatality in FcgRIIB−⁄−SLAM129 female mice 
start around 8- till 12-month old (36). Deficiency of gp49B in FcgRIIB−⁄−SLAM129 female 
mice reduced the serum titer of anti-dsDNA IgG significantly only at around 36-week old 
that marks the onset of autoimmunity, but not so profoundly at the later ages. The comparable 
titers of anti-dsDNA IgG between gp49B-sufficient and deficient FcgRIIB−⁄−SLAM129 mice 
are also reflected from the detection of pathogenic antibody-secreting cells (Fig. 2F), because 
mice used for the later detection were aged between 40- and 48-week old. Difference of 
effects of gp49B deletion noted between BXSB/Yaa and FcgRIIB−⁄−SLAM129 mice showed 
that variations still exist, despite both lupus-prone mice have commonalities to show a 
reduced titer of autoantibody. One possibility could be from the effect of FcgRIIB defect. 
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Although BXSB/Yaa mice and other SLE-prone mouse strains shared a common autoimmune 
Fcgr2 promoter haplotype (37), complete deletion of FcgRIIB may impact differently. From 
this aspect, it will be appealing to understand the possible interaction between these two 
inhibitory receptors in generation of pathogenic plasma cells.      
 
Integrin αvβ3 is reported to be the physiological ligand of gp49B (22, 38). Because the 
expression of integrin αvβ3 is found on various cell types (39), the ligation to integrin αvβ3 is 
controlled by its avidity state, which is upregulated only upon cellular activation (38, 40). For 
instance, integrin αvβ3 may ligate upon activated macrophages in response to pro-
inflammatory stimuli, which will cause a sustained inflammatory response (41). 
Macrophages also utilize integrin αvβ3 to remove apoptotic cells (42, 43). In the case of SLE, 
monocytes/macrophages recognize the phagocytosed cells as an inflammatory signal and 
present them as autoantigens to autoreactive B and T cells, which in turn initiate 
autoimmunity (44). These aspects of events, particularly focusing on the ligand–gp49B 
interaction in macrophages and plasma cells are potential targets for further analysis.    
 
One of the cellular abnormalities observed in BXSB/Yaa is the defective formation of 
marginal zone B (MZB) cells in the spleen. This defect is linked to the presence of the Yaa 
mutation in the B cells, regardless of the background, lupus-prone BXSB or wild-type 
C57BL/6 (29). It is suggested that the enhanced activation of Yaa-mutated MZB cells 
through the T-independent immune response mediated by dendritic cells prevents the 
accumulation of MZB cells (45). In our study, we observed an increase or recovery of the 
MZB cell population only in gp49B-deficient BXSB/Yaa mice, i.e., not in female BXSB 
mice (Fig. 4B and Supplementary Fig. S2A), implying the involvement of gp49B in the 
development of Yaa-bearing B cells into MZB cells. In Aiolos-deficient mice, follicular B 
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(FoB) cells exhibited enhanced maturation and reduction of CD21 expression, accompanied 
by a blockade of MZB cell formation. This is due to the elevated BCR or Btk activation 
resulting from the loss of Aiolos as the negative regulator (46). Aiolos-mutant mice were also 
reported to develop an SLE-like phenotype (47). We found that gp49 is expressed on FoB 
cells from BXSB mice with the Yaa mutation (Supplementary Fig. S2B), different from in 
the case of the C57BL/6 background reported (22), which suggests that gp49B possibly 
negatively regulates the Aiolos pathway, and thus enhances BCR or Btk activation in the Yaa 
background. This could explain the observation of the higher CD21 level on FoB cells from 
gp49B−⁄−BXSB mice with the Yaa mutation (Fig. 4C, and Supplementary Fig. S2C), and 
MZB cell recovery. The Yaa mutation with MZB cell loss is not associated with the 
development of lupus in BXSB mice. This is seen in BXSB.H-2d and BXSB.Eα mice that 
have a defect in the MZB cell compartment, but are protected from lupus manifestation (29, 
48, 49). Thus, even though MZB cells were regained in the gp49B-deficient BXSB/Yaa mice, 
this may not contribute significantly to the reduction of autoantibody IgG production 
indicated in Fig. 2C. 
 
In conclusion, although we failed to determine the exact mechanism for the underlying 
relationship between gp49B and disease progression, gp49B could be a marker for 
pathogenic plasma cells of lupus-prone mice. Depletion of plasma cells as well as other 
gp49B-positive pathogenic cells will most likely clarify the exact role of this inhibitory 
receptor in autoimmunity. 
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Figure 1. The expression level of gp49B on plasma cells. 
(A) Representative flow cytometry histograms of gp49 expression on marginal zone B cells 
from C57BL/6 and BXSB/Yaa mice.  
(B) Representative flow cytometry histograms of gp49 expression on the plasma cells from 
spleen and bone marrow from wild type mouse and SLE model mice (top). MFI of gp49 was 
normalized to that of isotype control antibody and data are represented as means ±  SEM 
from at least three individual experiments (bottom). P values calculated by one-way ANOVA 
with Dunn’s multiple comparisons test (C57BL/6 as control column) are represented in 
asterisk sign (*). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. P values calculated 
by two-tailed unpaired Student’s t-test with Welch’s correction are represented in dagger sign 
(†). † p < 0.05, †† p < 0.01, ††† p < 0.001, †††† p < 0.0001. 
 (C) Representative flow cytometry histograms of gp49 expression on splenic plasma cells 
from gp49B+⁄+ or gp49B−⁄− in BXSB/Yaa and B6.FcgRIIB-deficient SLAM129 
(FcgRIIB−⁄−SLAM129) mice.  
 
Figure 2. The relationship between gp49B expression and anti-dsDNA IgG serum titer. 
(A) Correlation between the gp49 expression level on splenic plasma cells from BXSB/Yaa 
mice and the serum titers of anti-dsDNA IgG (left) and IgM (right). P values were calculated 
using Pearson’s correlation coefficients with a two-tailed test.  
(B) Correlation between the gp49 expression level on splenic plasma cells from BXSB/Yaa 
mice and the age of mice (weeks). P value was calculated using Pearson’s correlation 
coefficients with a two-tailed test.  
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(C) Sera were collected from gp49B+⁄+ and gp49B−⁄−BXSB/Yaa mice. The levels of anti-
dsDNA IgG (left) and IgM (right) were determined by ELISA. Horizontal lines represent 
mean values ± SEM. P value is calculated by two-tailed paired Student’s t-test. * p < 0.05.  
(D) Sera were collected from gp49B+⁄+ and gp49B−⁄−FcgRIIB−⁄−SLAM129 at 4-week intervals 
from 24-weeks old to 48-weeks old. The levels of anti-dsDNA IgG (left) and IgM (right) 
were determined by ELISA. Horizontal lines represent mean values. P value was calculated 
by two-way ANOVA with Sidak’s multiple comparisons test. * p < 0.05. 
(E)  The total number (top) and frequency (bottom) of anti-dsDNA IgG- and IgM-secreting 
cells among sorted splenic plasma cells of gp49B+⁄+ and gp49B−⁄−BXSB/Yaa mice were 
determined by ELISpot assay. Horizontal lines represent mean values ± SEM. P value was 
calculated using two-tailed paired Student’s t-test for each group. * p < 0.05.  
(F)  The total number (top) and frequency (bottom) of anti-dsDNA IgG- and IgM-secreting 
cells from sorted splenic plasma cells of gp49B+⁄+ and gp49B−⁄−FcgRIIB−⁄−SLAM129 mice were 
determined by ELISpot assay. Horizontal lines represent mean values ± SEM. 
 
Figure 3. Partial amelioration of autoimmunity in gp49B−⁄−BXSB/Yaa mice. 
(A) Survival curves for BXSB/Yaa mice (gp49B+⁄+, n = 30; gp49B−⁄−, n = 18). Mice were 
monitored for survival until week 50. The median survival for gp49B+⁄+BXSB/Yaa mice is 
until week 26, while that for gp49B−⁄−BXSB/Yaa mice is undefined. P value is calculated by 
Log-rank (Mantel-Cox) test. 
(B) Representative images of kidney sections from gp49B+⁄+ and gp49B−⁄−BXSB/Yaa and 
female gp49B+⁄+BXSB mice stained with HE (above) and PAS (below). Original 
magnification, × 400. Scale bar, 100 µm.  
(C) Percentage of deposition of PAS positive material on glomerular area within Bowman’s 
capsule was calculated as depicted in Materials and Methods. Data are represented as means 
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± SEM from five individual experiments, excepting the plot of female gp49B+/+BXSB for 
single determination. P value is calculated by two-tailed paired Student’s t-test. 
 
Figure 4. Changes of cell populations in gp49B−⁄−BXSB/Yaa mice. 
(A) The frequencies of CD19+ B cells (left) and CD3+ T cell subsets (right) from spleens 
were analyzed by flow cytometry. Horizontal lines represent mean values ± SEM. P value is 
calculated by two-tailed paired Student’s t-test. * p < 0.05. 
(B) Representative flow cytometric data on follicular B cells (FoB) and marginal zone B cells 
(MZB), gated from CD19+ B cells of gp49B+⁄+ and gp49B−⁄−BXSB/Yaa mice (top). The 
frequencies of FoB and MZB are represented as means ± SEM (bottom). P value is calculated 
by two-tailed paired Student’s t-test. * p < 0.05, *** p < 0.001. 
 (C) Representative flow cytometric histogram of expression of CD21 on follicular B cells 
(top). The MFI of CD21 expression are represented as means ± SEM (bottom). P value is 
calculated by two-tailed ratio paired t-test. * p < 0.05. 
(D) Representative flow cytometric data on spleen monocytes (B220−CD11b+) of gp49B+⁄+ 
and gp49B−⁄−BXSB/Yaa mice (left). The frequencies of monocytes are represented as means 
± SEM (right). P value is calculated by two-tailed paired t-test.   
